TABLE 2.
Analytic strategy used to dissect MAb and autologous neutralization activities in patient plasma
| Analysis | Description | Analysis type | Formula/symbols |
|---|---|---|---|
| 1 | Trough MAb dose in plasma ( ) |
ELISA, ex vivo analysis of plasma samples |
 or  or 
|
| 2 | Inhibitory dose of MAb against the isolate in vitro ( ) |
TZM-bl neutralization assay, in vitro analysis of MAbs against viruses;  (μg/ml) determined by linear regression |
 or  or 
|
| 3 | Inhibitory doses of the MAbs in combination at fixed ratios of MAbs reflecting in vivo concentrations against the isolate in vitro ( ) |
TZM-bl neutralization assay, in vitro analysis of MAb combinations against viruses;  (μg/ml) determined by linear regression |
 or  or 
|
| 4 | Combination effects of the MAbs were assessed as interaction indices (Inx) according to the work of Loewe (9) using fixed ratios of MAbs reflecting in vivo concentrations | Inx determined according to the method of Loewe at 70% inhibition in TZM-bl neutralization assay in vitro | Inx70 = IC702G12(mix)/IC702G12 + IC702F5(mix)/IC702F5 + IC704E10(mix)/IC704E10 |
| 5 | Calculate expected MAb NTs |
 ,  , and  calculated from corresponding inhibitory doses, Inx70, and the measured plasma MAb level |
NT70MAb = (1/Inx70) · (DPlasma2G12/IC702G12 + DPlasma2F5/IC702F5 + DPlasma4E10/IC704E10) |
| 6 | Total plasma neutralization activity ( ) |
Ex vivo analysis of patient plasma in TZM-bl neutralization assay; reciprocal titer ( ) determined by linear regression |
 |
| 7 | Autologous plasma neutralization activity ( ) |
Calculation |  |